Evidence map›Paper›PMID 37918409›Full record

ArticleArchivos de cardiologia de Mexico2023

Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensión Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC).

Mario Speranza, Clara Saldarriaga, Carlos E Ramos, Daniel Quesada, Víctor Rossel, Jaime R Ventura-Umanzor, Freddy Pow-Chon, Walter Alarco, Yolanda Figueroa, Antonio Magaña and 2 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Archivos de cardiologia de Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mario SperanzaDepartamento de Cardiología, Hospital Clínica Bíblica, San José, Costa Rica.
Clara SaldarriagaDepartamento de Cardiología, Clínica Cardio VID, Medellín, Colombia.
Carlos E RamosDepartamento de Cardiología, Instituto Nacional Cardiopulmonar, Tegucigalpa, Honduras.
Daniel QuesadaDepartamento de Cardiología, Hospital San Vicente de Paul, Heredia, Costa Rica.
Víctor RosselDepartamento de Cardiología, Hospital del Salvador.
Jaime R Ventura-UmanzorDepartamento de Cardiología, Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador.
Freddy Pow-ChonDepartamento de Cardiología, Hospital Luis Vernaza.
Walter AlarcoDepartamento de Cardiología, Instituto Nacional Cardiovascular, Lima, Perú.
Yolanda FigueroaDepartamento de Cardiología, Legacy Medical Center, Humacao, Puerto Rico.
Antonio MagañaDepartamento de Cardiología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Juan E Gómez-MesaDepartamento de Cardiología, Fundación Valle de Lili, Cali, Colombia.
David Rodríguez-GarcíaDepartamento de Cardiología, Hospital Herrera Llerandi, Guatemala.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a significant event for public health. It has a prevalence between 1-2%, mortality rate between 7-17%, and hospitalization between 32-44%. This implies a risk to health and quality of life, but also great financial efforts for health systems. Sacubitril/valsartan is a medication recognized for its efficacy, and this consensus seeks to synthesize the available information regarding its use for the benefit of patients. This document consists of a description of the epidemiology of HF, pharmacology of the drug, clinical trials, use of the drug in cases with reduced ejection fraction, mildly reduced ejection fraction and preserved ejection fraction, available literature on HF guidelines, recommendations and conclusions.

Indexed as

CardiologyHeart FailureHypertensionVentricular Dysfunction, LeftAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsHumansQuality of LifeStroke VolumeTetrazolesUnited StatesValsartanAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundssacubitrilTetrazolesValsartanConsensoConsensusHeart failureInsuficiencia cardiacaSacubitrilo-valsartánSacubitril-valsartan

Identifiers

PMID37918409
PMCPMC10665007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.